169 reports of this reaction
2.2% of all DEXMETHYLPHENIDATE HYDROCHLORIDE reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for DEXMETHYLPHENIDATE HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 169 FDA adverse event reports linking DEXMETHYLPHENIDATE HYDROCHLORIDE to FATIGUE. This represents approximately 2.2% of all 7,728 adverse event reports for this drug.
Patients taking DEXMETHYLPHENIDATE HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for DEXMETHYLPHENIDATE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for DEXMETHYLPHENIDATE HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 169 FDA reports for DEXMETHYLPHENIDATE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.2% of all adverse event reports for DEXMETHYLPHENIDATE HYDROCHLORIDE, making it a notable side effect.
If you experience fatigue while taking DEXMETHYLPHENIDATE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.